Clebopride
Dopamine antagonist drug
- A03FA06 (WHO)
- 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-
2-methoxybenzamide
- 55905-53-8
Y
- 2780
- 2678 Y
- I0A84520Y9
- D03534 Y
- ChEMBL325109 Y
- DTXSID7022831
- Interactive image
- Clc1cc(c(OC)cc1N)C(=O)NC3CCN(Cc2ccccc2)CC3
InChI
- InChI=1S/C20H24ClN3O2/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25)Y
- Key:BVPWJMCABCPUQY-UHFFFAOYSA-NY
Clebopride is a dopamine antagonist drug with antiemetic and prokinetic properties used to treat functional gastrointestinal disorders. Chemically, it is a substituted benzamide, closely related to metoclopramide.
A small Spanish study found that more adverse reactions are reported with clebopride than with metoclopramide, particularly extrapyramidal symptoms.[1]
References
- ^ Cuena Boy R, Maciá Martínez MA (March 1998). "[Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]". Atencion Primaria (in Spanish). 21 (5): 289–95. PMID 9608114. Free full text Archived 2018-11-01 at the Wayback Machine
- v
- t
- e
- See also: Receptor/signaling modulators
- Adrenergics
- Serotonergics
- Monoamine reuptake inhibitors
- Monoamine releasing agents
- Monoamine metabolism modulators
- Monoamine neurotoxins
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
